NASDAQ:CUE Cue Biopharma Q2 2026 Earnings Results & Report $16.12 -1.38 (-7.89%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$16.32 +0.20 (+1.23%) As of 11/13/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cue Biopharma missed analyst earnings expectations but beat on revenue in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$24.14 versus the -$1.69 consensus estimate, while revenue of $7.88 million topped the $3 million estimate by $4.88 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 14, 2026TimeAfter Market ClosesConference Call7:00 AM ET Cue Biopharma EPS ResultsActual EPS-$24.14Consensus EPS -$1.69Beat/MissMissed by -$22.45One Year Ago EPSN/ACue Biopharma Revenue ResultsActual Revenue$7.88 millionExpected Revenue$3 millionBeat/MissBeat by +$4.88 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cue Biopharma Q2 2026 Earnings FAQ Did Cue Biopharma beat earnings estimates for Q2 2026? Cue Biopharma (NASDAQ:CUE) reported earnings of -$24.14 per share for Q2 2026, missing the consensus estimate of -$1.69. The report was announced on Friday, August 14, 2026. What was Cue Biopharma's revenue for Q2 2026? Cue Biopharma reported revenue of $7.88 million for Q2 2026, against a consensus estimate of $3 million. Cue Biopharma Earnings HeadlinesCue Biopharma (CUE) Set to Release Earnings on WednesdayNovember 10, 2026 | americanbankingnews.comCue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?September 26, 2026 | finance.yahoo.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 14 at 1:00 AM | Behind the Markets (Ad)Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOASeptember 21, 2026 | seekingalpha.comCue Biopharma Meets Primary Goal in a Phase 2 Study of Chronic Hives Disease Drug CandidateSeptember 21, 2026 | finance.yahoo.comCue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial ResultsSeptember 21, 2026 | finance.yahoo.comSee More Cue Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cue Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cue Biopharma and other key companies, straight to your email. Email Address About Cue BiopharmaCue Biopharma (NASDAQ:CUE) is a biotechnology company developing biologic medicines designed to selectively engage and modulate T cells. Its Immuno-STAT platform is intended to direct immune activity toward disease-specific targets, with potential applications in cancer and autoimmune disorders.The company’s research has included cancer candidates such as CUE-101, designed to target HPV16-positive cancers, and CUE-102, developed to target cancers expressing the WT1 protein. Cue Biopharma has also pursued programs intended to influence immune responses in autoimmune disease.Based in Cambridge, Massachusetts, Cue Biopharma works in the biotechnology sector. Its approach focuses on engineering biologics to shape the body’s T-cell response rather than broadly activating or suppressing the immune system.View Cue Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
